HCU Research Grants
Research grants are intended to support innovative seed or pilot projects to produce preliminary data that would facilitate more substantial funding from federal agencies, foundations, or corporations.
Grants Process
Calls for Expressions of Interest (EOI) are issued on a periodic basis (the goal is every 18 months) and are communicated through relevant organizations (e.g. SIMD, SSIEM, GMDI) and posted on our website.
EOI:
- Researchers are asked to submit an Expression of Interest (EOI) Application, not exceeding 2 pages, including a high-level description of the proposed project, potential budget range, and any conflict of interests with SAB members. EOIs are reviewed by the Global Scientific Advisory Board (SAB) and applicants are notified whether they are invited to submit a full Grant Application.
- Grant Applications are reviewed and scored by the SAB and by at least 2 independent reviewers who are considered experts in the specific scientific approach being recommended. Based on these evaluations, the SAB then recommends which proposal(s) are recommended for funding and the HCU Networks then make the final decision based on available funding.
- Most grants are awarded at the level of USD $50,000, though exceptions can be made depending on the specific project. Researchers must agree to submit an interim project update halfway through the grant period (which is usually 6-12 months), and a final report at the end of the project. Awardees may also be asked to present results to the SAB and/or to the patient community at periodic meetings or webinars.
- Researchers must agree to submit an interim project update halfway through the grant period (which is usually 12 months) and a final report at the end of the project. Awardees may also be asked to present results to the SAB and/or to the patient community at periodic meetings or webinars, and to publish the results.
2026 EOI: HCU Network America issued a call in March 2026 for Expressions of Interest (EOI) for research grants to address one of the following priorities:
- Novel proposals for treatment and prevention of clinical manifestations for Classical Homocystinuria and/or;
- Novel proposals for treatment and prevention of clinical manifestations for cobalamin G, a Methionine synthase deficiency
By exploring novel mechanisms to obtain proof of concept to enable progression to clinical trials.
EOI applications can be found here. 2026 HCU Network America Grant Application - Fill out form
You can learn more about the grants we have funded here.
Important Dates:
- EOI deadline for submission: May 31, 2026
- Notification of successful EOI: July 1, 2026
- Deadline for full applications: September 1, 2026
- Funding decisions will be made by November 1, 2026
Scientific Advisory Board
Professor Warren Kruger, (Co-chair of SAB); Ph. D, Full professor, Cancer Biology and Epigenetics program at Fox Chase Cancer Center, Philadelphia, PA, U.S. Read Professor Kruger's bio
Peter Baker (Co-chair), MD. Clinical Biochemical Genetics, Pediatrics. Colorado Children's Hospital. Read Dr. Baker's bio
Dr Andrew Morris, BM, BCh, PhD, Consultant and Senior Lecturer in Paediatric Metabolic Medicine, Willink Metabolic Unit, Manchester University Hospitals NHS Trust, UK. Read Dr. Morris' bio
Dr Kimberly Chapman, MD, Ph.D., Attending physician in medical genetics at Children’s Hospital Los Angelos, professor of Clinical Pediatrics, Keck School of Medicine of USC. Read Dr. Chapman's bio
Professor Matthias R. Baumgartner, Prof. Dr. med., head of Division for Metabolic Diseases and Medical Director of the Swiss Newborn Screening Program, University Children’s Hospital Zurich, Zürich, Switzerland. Read Professor Baumgartner's bio
Dr. Kaustuv Bhattacharya, Senior Staff Specialist, Sydney Children’s Hospitals Network, Sydney, Australia
Conjoint Senior Lecturer, Discipline of Child and Adolescent Health and Genomics, Sydney University. Read Dr. Kaustuv's bio
Professor Viktor Kožich, MD, PhD, Professor of Medical Genetics,
Department of Pediatrics and Inherited Metabolic Diseases, General University Hospital in Prague and Charles University-First Faculty of Medicine, Prague, Czech Republic. Read Professor Kožich’s bio
Sean Froese, PD. Principle Investigator, Division of Metabolism, University Children’s Hospital Zurich, Switzerland. Read his bio
Walla Al-Hertaini, MD, MS, FRCPC, FCCMG, FACMG. Chief of the Metabolic Disorders Division and medical director of metabolic disorders at Children’s Hospital of Orange County. Read Dr. Al-Hertaini's bio
Manuel Schiff. Assistance Publique Hospitaux de Paris-University Hospital Robert-Debra, France. Associate professor of Pediatrics. Head of the Reference Centre for Inborn Errors of Metabolism. Read his bio
David Rosenblatt, MD. McGill University. Dodd Q. Chu and Family Chair in Medical Genetics Professor, Departments of Human Genetics, Medicine, Pediatrics and Biology. Read his bio
Nicola Longo, MD, PhD, Professor and Chief of the Division of Clinical Genetics, Human Genetics at UCLA, David Geffen School of Medicine. Read Professor Longoi's bio
Patient Representatives:
Brittany Parke, HCU Network America, Research Coordinator
Margaret McGlynn, HCU Network America, Emeritus Board Member and Grant Advisor
Melanie Colter, CanPKU+ Board Member, HCU Representative, Parent to Masen, Classical HCU
Grace Talbert, HCU Network America, Community Engagement Coordinator
Renske Dijkhuis, HCU Network Australia, Patient Representative
Tara Morrison, HCU Network Australia
For more information, email Brittany Parke at grants@hcunetworkamerica.org
